Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous nano-fat + platelet-rich fibrin is a combination regenerative therapy being developed by the Affiliated Hospital of Guangdong Medical University for the treatment of chronic wounds, particularly diabetic foot ulcers (DFUs). Nano-fat is an emulsified form of autologous adipose tissue that is rich in adipose-derived stem cells (ADSCs) and essential extracellular matrix components, but depleted of mature adipocytes. Platelet-rich fibrin (PRF) is a second-generation platelet concentrate that forms a natural fibrin scaffold, providing a reservoir for the sustained release of growth factors, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β). The combination aims to overcome the impaired healing environment of diabetic wounds by promoting neovascularization, reducing inflammation, and accelerating epithelialization and collagen deposition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous nano-fat + platelet-rich fibrin.